Eli Lilly invests US$4.5B more in Indiana manufacturing to increase production capacity

USA—Eli Lilly has pledged an additional US$4.5 billion to expand production capabilities at two of its three planned manufacturing facilities in Lebanon, Indiana.

The announcement came during a ribbon-cutting ceremony for the company’s genetic medicine plant, marking the first operational facility at the sprawling 600-acre site located 28 miles northwest of Lilly’s Indianapolis headquarters.

This latest investment reinforces the company’s commitment to domestic manufacturing, building on an already substantial pledge.

Since 2020, Eli Lilly has committed over US$50 billion to strengthen U.S. production, with more than US$21 billion directed specifically toward Indiana operations.

Expanding capacity to meet growing demand

The additional funding will enhance two key facilities within the Lebanon complex, known collectively as the LEAP Research and Innovation District.

The first facility, Lilly Lebanon Advanced Therapies, focuses on clinical and commercial production of gene-targeted medications designed to prevent disease at the molecular level.

The company noted that manufacturing these therapies required developing entirely new production processes without established industry precedents.

The second facility, Lilly Lebanon API, will produce active pharmaceutical ingredients for the company’s blockbuster medications.

Once complete, this plant will become the largest active pharmaceutical ingredients facility in the United States.

It will manufacture tirzepatide, the key component of Mounjaro for diabetes and of Zepbound for weight loss, alongside newer treatments, including Foundayo, a recently launched oral obesity medication, and retatrutide, an investigational drug targeting multiple hormone receptors.

These products address major market needs, particularly in diabetes and obesity treatment, where demand continues to accelerate globally.

The broader manufacturing vision

Lebanon’s third planned facility, the Lilly Medicine Foundry, is set to open in 2027 with a US$4.5 billion budget.

This 1.2-million-square-foot complex will integrate research, development, and clinical-trial manufacturing for small molecules and biologics targeting cancer, diabetes, and Alzheimer’s disease.

Ground was broken at the Lebanon site in April 2023.

According to David Ricks, Eli Lilly’s chief executive officer, the facility represents the company’s ongoing legacy of innovation in Indiana while positioning it to manufacture the medicines of tomorrow at the world’s most advanced production plants.

National expansion and economic impact

Beyond Indiana, Eli Lilly announced a US$27 billion USD plan in February 2025 to build four additional production facilities across the nation.

These include active pharmaceutical ingredient plants in Virginia, Alabama, and Houston, Texas, with investments of US$5 billion, US$6 billion and US$6.5 billion, respectively.

An injectables facility in Pennsylvania will receive US$3.5 billion in funding.

At the state level, Eli Lilly’s economic footprint is substantial.

According to a report from Indiana University’s Kelley School of Business to be released soon, the company represents 70 percent of Indiana’s pharmaceutical economic output.

Additionally, each Lilly job supports more than two additional jobs throughout the state.

Local and state governments have contributed financially to support the development of the Lebanon campus.

Strategic response to government incentives

Eli Lilly’s expansion comes amid broader industry momentum toward domestic production.

Since assuming office last year, President Donald Trump has leveraged tariff threats to encourage major manufacturers to keep operations in the United States.

The strategy has proven effective, with major pharmaceutical companies including Johnson & Johnson, Novartis, Roche, Gilead, Bristol Myers Squibb, and AstraZeneca announcing significant investments in U.S. manufacturing.

Collectively, these industry pledges reached US$370 billion in 2025, according to data from DPR Construction, signalling a major shift toward reshoring pharmaceutical manufacturing and strengthening domestic supply chains.